Results 81 to 90 of about 29,991 (269)

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital   +13 more
wiley   +1 more source

Insights into mucosal associated invariant T cell biology from human inborn errors of immunity [PDF]

, 2022
Lauren J. Howson, Vanessa L. Bryant
openalex   +1 more source

Differences in IgG Sialylation Distinguish Asymptomatic From Symptomatic Antinuclear Antibody–Positive Individuals

Arthritis &Rheumatology, EarlyView.
Objective The transition from asymptomatic antinuclear antibody (ANA) positivity to systemic autoimmune rheumatic disease (SARD) is associated with increased production of proinflammatory factors such as tumor necrosis factor α (TNFα). Here we investigate whether the relative absence of inflammation in asymptomatic ANA+ individuals (ANA+NS) results ...
Carolina Muñoz‐Grajales, Carmen C. Ucciferri, Sindhu R. Johnson, Zahi Touma, Zareen Ahmad, Dennisse Bonilla, Linda T. Hiraki, Arthur Bookman, Joan E. Wither   +8 more
wiley   +1 more source

Inborn Errors of Immunity: how to diagnose them?

, 2021
Anete Sevciovic Grumach, Ekaterini Goudouris   +1 more
openalex   +1 more source

Is susceptibility to severe COVID‐19 disease an inborn error of metabolism? [PDF]

, 2020
Peter T. Clayton
openalex   +1 more source

Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome

Arthritis &Rheumatology, EarlyView.
Serum cytokine profiling was performed using Luminex (48 cytokines) and ELISA (5 cytokines). Assessment of key cytokines (IFN‐α, IL‐18, IL‐6, CXCL9) delineated five dominant inflammatory patterns: I, IFN‐α–dominant CSS; II, IL‐18–dominant CSS; III, IL‐6–dominant CSS; IV, IFN‐γ–dominant CSS; and V, IL‐6 & IFN‐γ intermediate CSS.
Shuya Kaneko, Maho Hatano, Asami Shimbo, Futaba Miyaoka, Hitoshi Irabu, Yuko Akutsu, Yuko Hayashi, Mao Mizuta, Yasuo Nakagishi, Keiji Akamine, Naomi Iwata, Kenji Furuno, Takayuki Tanaka, Kazuyuki Ueno, Shuhei Fujita, Koji Yokoyama, Toshinori Minato, Kazushi Izawa, Takahiro Yasumi, Tadashi Matsubayashi, Tadashi Hosoya, Hiroki Nishikawa, Junya Fujimura, Ryoko Asano, Yuko Sugita, Kenichi Watanabe, Anna Kobayashi, Takuya Endo, Katsuhide Eguchi, Ryuta Nishikomori, Ryuhei Yasuoka, Takaki Asano, Miyako Kanno, Kazuya Hamada, Yuji Fujita, Daisuke Hayashi, Shojiro Watanabe, Takeshi Shiba, Shinsuke Yasuda, Masaaki Mori, Hirokazu Kanegane, Masatoshi Takagi, Masaki Shimizu   +42 more
wiley   +1 more source

Pulmonary Involvement in Adult Patients with Inborn Errors of Metabolism [PDF]

, 2017
Christel Tran, Frédéric Barbey, Romain Lazor, Luisa Bonafé   +3 more
openalex   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Research progress on renal calculus associate with inborn error of metabolism

, 2023
Yuanming Song, Changyong Zhao, Daobing Li   +2 more
openalex   +1 more source

Diagnostic implications and correlates of plasma ADA2 activity and ADA2 variants

Arthritis &Rheumatology, Accepted Article.
Objectives Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2
Jian Yue, Courtney E. LeSon, Casey A. Rimland, Kailey Brodeur, Rachel Weng, Evan E. Hsu, Michael T. Lam, Manpreet Meyer, Seigo Okada, Andrew L. D. Hsu, Musaab A. Alhezam, Megan M. Perron, Olha Halyabar, Fatma Dedeoglu, Peter A. Nigrovic, Akiko Shimamura, R. Grant Rowe, Megan A. Cooper, Tiphanie P. Vogel, Miriah Gillispie‐Taylor, Rosemary Peterson, Clara Lin, Katherine D. Nowicki, Kaylee Dollerschell, Taizo A. Nakano, Roxane Labrosse, Alexis‐Virgil Cochino, Andreea Ioan, Leonardo Oliveira Mendonca, Samar Freschi Barros, Jorge Kalil, Javier Perez Rojas, Alicia Diaz Kuan, Eric S. Sobel, Taha Moussa, Samuel Shang Ming Lee, Li Wearn Koh, Archana Khan, Sodality Sutnga, Raju Khubchandani, Walaa Shoman, Yasmine El Chazli, Benzeeta Pinto, Chengappa Kavadichanda, Roshini S. Abraham, Xiangwei Sun, Qing Zhou, GSRSNK Naidu, Aman Sharma, Carl Esperanzate, Daniel L. Kastner, Ivona Aksentijevich, Susan J. Kelly, Michael Hershfield, Teresa K. Tarrant, Pui Y. Lee   +55 more
wiley   +1 more source